Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: Some issues.
Published in Journal of viral hepatitis
Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinic...
...Published in Journal of viral hepatitis
Direct-acting antiviral (DAA) treatment for hepatitis C (HCV) has been readily available since March 2016 in Australia. Around 80,000 people have been treated to date, however testing and treatment numbers have plateaued, and current rates may not be high enough to reach HCV elimination targets. In 2019, the Eliminate Hepatitis C Victoria Partnersh...
No evidence of sexual transmission of HEV among individuals using HIV pre-exposure prophylaxis.
Published in Journal of viral hepatitis
We investigated the seroprevalence and incidence of hepatitis E virus (HEV) infection in men who have sex with men (MSM) who have been exposed to pre-exposure prophylaxis (PrEP) against HIV as sexual transmission of HEV has been suggested. A total of 147 PrEP-using MSM and 147 blood donors matched for sex, age and geographical area were tested for ...
Bayesian network to predict hepatitis B surface antigen seroclearance in chronic hepatitis B patients.
...Published in Journal of viral hepatitis
There is a need for an interpretable, accurate and interactions-considered model for predicting hepatitis B surface antigen (HBsAg) seroclearance. We aimed to construct a Bayesian network (BN) model using available medical records to predict HBsAg seroclearance in chronic hepatitis B (CHB) patients, and to evaluate the model's performance. This was...
Disease burden of viral hepatitis A, B, C and E: A systematic analysis.
Published in Journal of viral hepatitis
Viral hepatitis has been recognized as a leading cause of deaths worldwide. We aimed to analyse the disease burden of viral hepatitis at the global, regional and national levels. We collected the data of death number, mortality rate, and disability-adjusted life years (DALYs) of viral hepatitis by sex, age, geography and type of disease from the Gl...
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients.
...Published in Journal of viral hepatitis
Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients even under effective long-term oral antiviral therapy, but its pathogenesis in the setting of long-standing inhibition of viral replication has not been completely elucidated. We investigated whether species of circulating cell-free DNA (cfDNA) may be involved in...
Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients?
Published in Journal of viral hepatitis
Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study.
...Published in Journal of viral hepatitis
Although glucocorticoids have been used for immunosuppression of patients with primary hepatitis B virus (HBV) infection-induced severe hepatitis, the treatment is associated with a high frequency of adverse events. We conducted a pilot study for evaluating the efficacy and safety of abatacept, a cytotoxic T lymphocyte antigen-4 immunoglobulin (CTL...
Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer bir...
Published in Journal of viral hepatitis
We examined mortality trends of hepatitis C virus (HCV) infection in the United States in 1999-2018 according to the following definitions: HCV as the underlying cause of death (UCOD), HCV mentioned anywhere on the death certificate (mentioned), and HCV recorded in Part 1 of the death certificate. By using entity axis information in mortality multi...
Intrahepatic T helper 17 cells recruited by hepatitis B virus X antigen-activated hepatic stellate cells exacerbate the ...
Published in Journal of viral hepatitis
Immunopathological injury induced by persistent hepatitis B virus (HBV) infection contributes to the progression from chronic hepatitis B (CHB) to hepatic cirrhosis and hepatocellular carcinoma (HCC). Regulatory T cells (Tregs), CD4+ T helper (Th) cells, and hepatic stellate cells (HSCs) are considered to be the pivotal factors during this progress...
